Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.

导出 OA

翻译打印收藏纠错

作者： Kerri,Basile ^[1] ; Rebecca J,Rockett ^[2] ; Kenneth,McPhie ^[3] ; Michael,Fennell ^[1] ; Jessica,Johnson-Mackinnon ^[4] ; Jessica E,Agius ^[1] ; Winkie,Fong ^[2] ; Hossinur,Rahman ^[2] ; Danny,Ko ^[2] ; Linda,Donavan ^[1] ; Linda,Hueston ^[1] ; Connie,Lam ^[1] ; Alicia,Arnott ^[1] ; Sharon C-A,Chen ^[5] ; Susan,Maddocks ^[2] ; Matthew V,O'Sullivan ^[1] ; Dominic E,Dwyer ^[1] ; Vitali,Sintchenko ^[2] ; Jen,Kok ^[3]

作者单位： Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia. ^[1] Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia. ^[2] Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW 2006, Australia. ^[3] The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2145, Australia. ^[4] Menzies Health Institute Queensland, Griffith University, Brisbane, QLD 4222, Australia. ^[5]

关键词 COVID-19 Omicron Pfizer-BioNTech BNT162b2 SARS-CoV-2 VOC immunity neutralising antibodies vaccine

主题词抗体, 中和(Antibodies, Neutralizing);抗体, 病毒(Antibodies, Viral);人类(Humans);疫苗(Vaccines);病毒包膜蛋白质类(Viral Envelope Proteins)

DOI 10.3390/v14092023

PMID 36146829

发布时间 2022-10-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交